Track record · closed signal

AbbVie Inc. (ABBV) — closed signal from December 18, 2025

Partial Published before the outcome was known, scored automatically when the window closed on March 18, 2026 — -7.5% at the close.

Predicted vs. what happened

ABBV price · publication thesis → realized outcomesplit-adjusted

$220.00 – $226.00Entry zone — fair-value band

$225.12Published — price the day we called it

$247.63Target — the price the thesis aimed for

$237.11Peak — highest point inside the window, not a realized return

$208.34Window close — end-of-window price, context only

What happened

Partial

Reached 53% of the predicted growth at its peak, without hitting the target.

At window close

-7.5%

realized, from the publication price to the last close inside the window

Peak gain

+5.3%

peak, from the publication price — not a realized return

S&P 500, same window

-1.9%

SPY over the identical days, dividend-adjusted

Window close

$208.34

last close inside the window, ended March 18, 2026

Peak price

$237.11

peak on March 4, 2026 — not a realized return

Days to target

—

The thesis — published December 18, 2025

Predicted growth

+10%

over the measurement window

Target price

$247.63

the price the thesis aimed for

Entry zone

$220.00 – $226.00

the fair-value band we waited for

Price at publication

$225.12

published December 18, 2025

Confidence

63%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

The stock looks like a cautious bounce, not a clear long-term trend. Analysts disagree-one cut the price target while another raised it-so the likely outcome is sideways gains. A short-term momentum reading is very low but the short-term trend signal still looks weak, so gains may come slowly over a few months. Start small and wait for clearer strength.

Primary drivers

Analyst upgrade vs target cut supports a sideways rebound
Very low momentum reading can trigger a short-term rebound
Money moving into healthcare could help amid tech swings
Positive drug pipeline talk lifts sentiment despite weak fundamentals

How it played out

ABBV: target was not reached

Lyra published ABBV at $225.12 on 2025-12-18 with expected growth of 10%. The thesis called it a cautious bounce, not a clear long-term trend. It pointed to mixed analyst signals, a very low momentum reading, possible healthcare inflows, and positive drug pipeline talk.

Inside the window, ABBV rose to a peak of $237.11 on 2026-03-04, a 5.3% gain. It stayed below the $247.63 target and never reached it. By 2026-03-18, it ended at $208.34. The thesis partially played out because the stock did rebound, but the move fell short and then faded.

What happened during the window

On 2026-02-04, AbbVie reported fourth-quarter results with revenue of $16.62 billion and adjusted earnings of $2.71 per share. The same day, coverage reported that the stock fell after the release despite the beat.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All ABBV signals